Navigation Links
Essure Procedure Now Covered by Medicaid in California

MOUNTAIN VIEW, Calif., May 14 /PRNewswire-FirstCall/ -- Conceptus, Inc. (Nasdaq: CPTS) developer of the Essure(R) procedure, the first and only non-incisional permanent birth control method available, today reported that Medi-Cal, California's state fee-for-service Medicaid program, is now covering the Essure procedure. Low-income or disabled women in California now have a safe and effective permanent female birth control option that does not require the general anesthesia, incisions or long recovery period of traditional tubal ligation.

"We are very happy that Medi-Cal has completed its review of the safety and efficacy of the Essure device and has established coverage for this procedure," said California Assembly Speaker pro Tem Sally Lieber. "This is a great day for the women of California covered by Medicaid, who will now be able to avoid the risks and long recovery times associated with traditional tubal ligation surgery."

The Essure procedure is now a covered procedure for Medi-Cal beneficiaries that are 21 years of age or older. Physicians may perform the Essure procedure in the physician's office, the ambulatory surgery center or the hospital outpatient department. Medi-Cal is expected to pay $2,282 as a global fee for an in-office procedure. This coverage decision impacts approximately 3.8 million Californians.

Coverage of the Essure procedure enables state Medicaid programs to provide a safe, convenient and economical choice for preventing pregnancies. In addition, the shorter recovery time-typically one day as compared with four to six days for the traditional laparoscopic procedure-means a faster return to work or home responsibilities. California joins 45 other states now covering the Essure procedure for women enrolled in Medicaid. Conceptus has yet to receive Medicaid decisions for the Essure procedure in Arizona, Nebraska, North Dakota, Utah and Washington.

"We continue to provide compelling information on the costs and benefits of the Essure procedure to those few remaining state Medicaid programs that have not given a coverage decision, and to lobby for improved payment in those states with poor reimbursement," commented Mark Sieczkarek, president and chief executive officer of Conceptus. "This positive coverage decision from Medi-Cal is an important step in our efforts to make Essure available to women from all socioeconomic backgrounds."

About the Essure Procedure

The Essure procedure, approved by the FDA in 2002, is a permanent birth control procedure that replaces tubal ligation for women. In the comfort of a physician's office and in about 10 minutes, the soft micro-inserts are placed into the Fallopian tubes through the cervix eliminating the need for incisions. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the Fallopian tubes.

The Essure confirmation test is performed three months after the procedure to confirm that the micro-inserts are in the correct location, the tubes are blocked and that the woman can discontinue temporary birth control. The Essure procedure is 99.80% effective and is the first and only FDA approved female sterilization procedure to have zero pregnancies in clinical trials.

About Conceptus

Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.

Additional information about the Essure procedure is available at or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at or by calling 1-877-ESSURE2.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Discussions regarding the continued availability of Medicaid coverage, and the Company's ability to obtain Medicaid coverage from additional states, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors such as strategic planning decisions by management, re-allocation of internal resources, decisions by insurance companies, scientific advances by third parties, and introduction of competitive products, as well as those factors set forth in the Company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and other filings with the Securities and Exchange Commission.

Contact Information:

Ashley Biever

310-577-7870 x 111

SOURCE Conceptus, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Aspirin at Bedtime Lowers Blood Pressure
2. High Blood Pressure, Cholesterol Associated With Eye Disease
3. High Blood Pressure Still Slipping Past Doctors
4. Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life, Including Pregnancy
5. Double duty: Loss of protective heart failure protein causes high blood pressure
6. Simple Steps Lead to Better Blood Pressure Control
7. Blood pressure killing the worlds workers while banks and drug firms stand idle
8. High blood pressure still sneaking past doctors, Stanford study shows
9. Study Reveals Women Feeling Growing Financial Pressures on Family Life
10. High Blood Pressure May Be Buffer Against Headaches
11. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone ... member, close friend, or animal pass away, death lives among us. It is your ... Coming from a family of 11 children, author T Sky understands that she may ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... IL (PRWEB) , ... November 30, 2015 , ... The ... an emerging pharmaceutical company. Because it is so important to this key industry segment, ... Factors in your IND Filing” on December 4th at 11am EST. , Federal law ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. ... Surgical Mesh technology for soft tissue repair in the US via Insightra’s national ... resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 months ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... & Laser Center is one of a select few plastic surgeons in the ... non-surgical fat removal. , SculpSure™ is the world’s first heat-induced laser treatment for ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- Booth #4303 – The Imaging Components business of Varian ... array of products in a new booth (#4303) at the ... America in Chicago this ... components "At the Heart of Imaging." Products will include a ... Claymount brand, and computer-aided diagnostic software from MeVis as well ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
Breaking Medicine Technology: